10-K: Exagen Inc. Reports 15.3% Revenue Growth in 2023, Driven by AVISE CTD Test Adoption and Reimbursement Improvements

Exagen Inc., a diagnostics company specializing in autoimmune diseases, announced a 15.3% increase in revenue for 2023, reaching $52.5 million, primarily attributed to the increased adoption of its flagship AVISE CTD test and improved commercial payor average selling price (ASP).

Summary

• Exagen Inc. reported a 15.3% increase in revenue for the year ended December 31, 2023, compared to the previous year, totaling $52.5 million.
• The revenue growth was primarily driven by improved commercial payor ASP, increased AVISE CTD year-over-year volume and cash collections from tests performed in prior periods, partially offset by decreased Medicare ASP.
• The company delivered 137,650 AVISE CTD tests in 2023, a 2% increase from 2022.
• The number of ordering healthcare providers decreased slightly to 2,383 in Q4 2023, compared to 2,419 in the same period in 2022.
• Exagen's net loss for 2023 was $23.7 million, an improvement from the $47.4 million net loss in 2022.
• Operating expenses decreased by 16.229 million in 2023 primarily due to decreases in personnel costs, marketing expenses, insurance expenses, third-party billing expenses, legal expenses, lab supplies expenses, collaboration expenses, clinical study expenses, and professional service fees.
• The company implemented several revenue cycle management initiatives in 2023, including withholding the submission of commercial payor claims for reimbursement until subsequent quarters, increasing appeals efforts, and implementing increases to its patient payment rates.
• Exagen's current cash and cash equivalents, along with anticipated future revenue, are projected to be sufficient to meet cash requirements for at least the next 12 months.

Sentiment

Score: 7

Explanation: The company demonstrated positive revenue growth, improved gross margin, and a reduction in net loss, indicating progress towards financial stability. However, the ongoing net losses, reliance on a limited number of products, and the competitive landscape warrant a cautiously optimistic outlook.

Positives

• Revenue increased by 15.3% in 2023 compared to 2022, reaching $52.5 million.
• Gross margin improved significantly to 56.1% in 2023 from 46.9% in 2022.
• The company successfully implemented revenue cycle management initiatives, leading to improved commercial payor ASP.
• Exagen continues to demonstrate a solid track record of commercial growth with its AVISE CTD test.
• The company maintains strong relationships with multiple rheumatology care management organizations (Super Groups).
• Exagen has a strong focus on research and development, with a pipeline of innovative testing products.
• The company has a specialized sales force and extensive network of relationships with rheumatologists.
• Exagen is committed to providing clarity in autoimmune disease decision-making and improving patients' clinical outcomes.

Negatives

• The company experienced a slight decrease in the number of ordering healthcare providers in Q4 2023.
• Exagen continues to operate at a net loss, although the loss decreased from $47.4 million in 2022 to $23.7 million in 2023.
• The company faces challenges related to commercial payor claim processing and revenue.
• Exagen is reliant on sole suppliers for some critical reagents, equipment, and materials.
• The company's ability to raise capital under its current shelf registration statement is limited by the 'baby shelf rule' due to its public float being less than $75 million.

Risks

• The company may not be able to achieve or maintain profitability.
• Third-party payors may not provide adequate coverage and reimbursement for Exagen's testing products.
• The company may be unable to manage growth effectively.
• Market acceptance of the company's testing products may not be achieved or maintained.
• The company may face difficulties in securing supplies from sole suppliers.
• The company may be unable to support demand for its testing products.
• Competition in the diagnostics industry is intense.
• Developing new testing products is a lengthy and complex process with no guarantee of success.
• The company's sole clinical laboratory facility could be damaged or become inoperable.
• The company may require substantial additional capital, which may not be available on acceptable terms.
• The company operates in a heavily regulated industry and is subject to numerous statutes and regulations.
• The FDA may determine that the company's tests are subject to regulation as medical devices.
• The company may be unable to maintain intellectual property protection.
• The company may fail to comply with obligations under license agreements.
• The company's stock price may be volatile.
• Future sales of shares by existing stockholders could cause the stock price to decline.
• Provisions in the company's charter documents and Delaware law could discourage a takeover.
• The company may be subject to cybersecurity breaches or data loss.
• Inflationary pressures could adversely affect the company's business and financial results.

Future Outlook

Exagen expects to continue to devote substantially all of its resources to increase adoption of, and reimbursement for, its testing products and to develop future testing products. The company anticipates that it will continue to incur net losses into the foreseeable future. Exagen believes that its existing cash and cash equivalents and anticipated future revenue will be sufficient to meet its anticipated cash requirements for at least the next 12 months.

Industry Context

Exagen operates in the rapidly evolving autoimmune disease diagnostics market. The company's focus on providing clarity in the diagnosis, prognosis, and monitoring of complex autoimmune diseases positions it to address a significant unmet need in rheumatology. The increasing prevalence of autoimmune diseases and the demand for more accurate and efficient diagnostic tools are driving growth in this market.

Comparison to Industry Standards

• Exagen's AVISE CTD test, which includes the proprietary AVISE Lupus test, offers a comprehensive panel for differential diagnosis of connective tissue diseases, which is a differentiator compared to traditional methods that often involve testing for individual biomarkers serially.
• The AVISE Lupus test demonstrated 80% sensitivity and 86% specificity for SLE in a clinical validation study, which compares favorably to the sensitivity and specificity of standard tests like ANA and anti-dsDNA.
• The CAPSTONE study demonstrated a 6x increased odds of establishing a new SLE diagnosis with AVISE Lupus [+] vs. tANA[+], and a 3x increased odds of initiating one or more SLE treatments with AVISE Lupus [+] vs. tANA[+].
• Compared to competitors like LabCorp, Quest, ARUP, and Mayo Clinic, Exagen's specialized focus on autoimmune diseases and its proprietary CB-CAPs technology provide a competitive advantage.
• Exagen's AVISE MTX test is included in the clinical guidelines of multiple rheumatology care management organizations (Super Groups), indicating recognition of its clinical utility compared to standard methotrexate monitoring methods.

Management Changes

Legal Proceedings

• In October 2023, the Company resolved an investigation with the U.S. Attorneys Office for the District of Massachusetts that was initiated by a qui tam lawsuit. Pursuant to a Settlement Agreement, the Company made a single lump-sum remittance to the government in the amount of $0.7 million in connection with specimen processing arrangements that Exagen historically had with physicians. The U.S. Attorneys Office dismissed this covered conduct in the qui tam lawsuit with prejudice, while non-covered conduct was dismissed without prejudice. In November 2023 the complaint was unsealed and served on Exagen. Exagen filed a motion to dismiss the complaint. In December 2023, the Company's insurance carrier provided reimbursement for certain defense costs the Company incurred in the October 2023 qui tam lawsuit. In February 2024, the relator filed a motion for leave to amend the complaint. Exagen opposed this motion, and all motions are still pending. The Company intends to vigorously defend against the claims being asserted in the complaint.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises, stock price volatility.
• Employees: Potential impact from changes in management and organizational structure.
• Customers: Improved diagnostic and monitoring solutions for autoimmune diseases.
• Suppliers: Continued reliance on sole suppliers for certain materials presents a risk.
• Creditors: Impacted by the company's ability to meet its debt obligations.

Next Steps

• Continue to focus on driving adoption and increasing reimbursement for AVISE CTD.
• Further develop and commercialize new testing products in the pipeline.
• Expand the company's presence within the autoimmune disease market.
• Continue to engage with payors to secure broader coverage and reimbursement.
• Monitor and adapt to changes in the regulatory environment.
• Pursue strategic partnerships and collaborations to enhance the company's offerings and market reach.

Key Dates

Keywords

autoimmune disease diagnostics, connective tissue disease testing, rheumatology, AVISE, systemic lupus erythematosus, SLE, rheumatoid arthritis, RA, biomarkers, CB-CAPs, EC4d, BC4d, clinical laboratory, reimbursement, commercial payors, Medicare, Medicaid, CLIA, CAP, FDA, LDT, diagnostics, precision medicine